Background: Many new targeted cancer drugs have received FDA approval based on
durable responses in nonrandomized controlled trials (non-RCTs). The goal of this study …

The management of non-small cell lung cancer (NSCLC) has transformed with the discovery
of therapeutically tractable oncogenic drivers. In addition to activating driver mutations, gene …

Background Programmed death‐ligand 1 (PD‐L1) expression is associated with clinical
outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) …

Risk factors for cancer-associated thrombosis are commonly divided into three categories:
patient-, cancer-, and treatment-related factors. Currently, different types of drugs are used in …

The treatment of advanced non–small-cell lung cancer (NSCLC) has undergone a paradigm
shift in the last decade. Molecular characterization of the disease has led to the rapid …

Brigatinib is a kinase inhibitor indicated for patients with advanced anaplastic lymphoma
kinase–positive non‐small cell lung cancer who progressed on or are intolerant to crizotinib …

Formalin‐fixed paraffin‐embedded (FFPE) tissues used for routine pathological diagnosis
are valuable for cancer genomic analysis; however, the association between mutation status …

Background Historically, older patients with advanced lung cancer have often received no
systemic treatment. Immunotherapy has improved outcomes in clinical trials, but its …

Background Patients with anaplastic lymphoma kinase-rearranged (ALK+) non–small cell
lung cancer (NSCLC) treated with crizotinib inevitably relapse, with brain as common site of …

Background Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumours
characterised by an activation of the janus kinase (JAK)/signal transducers and activators of …